U.S. regulators have delayed a decision on a proposed new anti-clotting drug from Bristol-Myers Squib Co. (BMY) and Pfizer Inc. (PFE) by three months to June 28, after the companies provided new information to the agency.
Bristol-Myers and Pfizer didn't specify what new information they submitted, but any delay in the introduction of the drug--Eliquis--may reduce 2012 sales versus Wall Street expectations. Sanford Bernstein analyst Tim Anderson had been expecting sales of Eliquis to total $395 million for 2012, but said Thursday that this estimate may have to be revised slightly.
Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.” Email: jackfriday2011(at)hotmail.co.uk
Thursday, March 01, 2012
US FDA Delays Decision On Bristol/Pfizer Anti-Clot Drug | Fox Business
via foxbusiness.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment